Get the Stockscreener App
3.65
0.54%
-0.02
Molecular Partners Ag Adr stock is traded at $3.65, with a volume of 3,304.
It is down -0.54% in the last 24 hours and down -13.10% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
See More
Previous Close:
$3.67
Open:
$3.67
24h Volume:
3,304
Relative Volume:
1.35
Market Cap:
$139.81M
Revenue:
$786.00K
Net Income/Loss:
$-72.06M
P/E Ratio:
-1.8957
EPS:
-1.9254
Net Cash Flow:
$-59.83M
1W Performance:
-4.20%
1M Performance:
-13.10%
6M Performance:
-13.10%
1Y Performance:
-4.20%
1-Day Range:
$0.00
$0.00
1-Week Range:
$3.52
$3.88
52-Week Range:
$3.52
$5.36
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
3.65 | 139.81M | 786.00K | -72.06M | -59.83M | -1.9254 |
VRTX
Vertex Pharmaceuticals Inc
|
508.46 | 128.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.59 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.61 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | H.C. Wainwright | Buy |
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners AG (MOLN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Molecular Partners AG (MOLN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Molecular Partners AG (MOLN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
MOLN Q2 2026 Earnings: Reported Loss of -$0.35 per ADS, No Revenue, Shares Slip 3.28% - careplusvn.com
MOLN Q2 2026 Earnings: Reported Loss of -$0.35 per ADS, No Revenue, Shares Slip 3.28%Surprise Factor Analysis - dars.gov.et
Nyxoah SA (NYXH) Stock Price & News - Syfe
Molecular Partners AG (MOLN) Peer Comparison – Compare with Others - Value Research
Why Does Molecular Partners (NASDAQ:MOLN) Update Matter Today? - Kalkine Media
Molecular (MOLN) Latest Quarter: EPS Beats Its Estimate in the Latest Reading; Price Move: Shares Move 4.02% Higher in the Latest ReadingSurprise Factor Analysis - careplusvn.com
Molecular (MOLN) Latest Quarter: EPS Beats Its Estimate in the Latest Reading; Price Move - dars.gov.et
Molecular (MOLN) Latest Quarter: EPS Beats Its Estimate in the Latest Reading; Price Move: Shares Move 4.02% Higher in the Latest ReadingEarnings Weakness Phase - dars.gov.et
Molecular (MOLN) Latest Quarter: EPS Beats Its Estimate in the Latest Reading; Price Move: Shares Move 4.02% Higher in the Latest ReadingGuidance Revision Trend - dars.gov.et
Molecular (MOLN) Outlook: Adds 3.55% to Close at $4.38 on the Day; Key Range: the Supplied Trading Band Runs From $4.16 to $4.60 on the DayETF AUM Growth - dars.gov.et
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%New Analyst Coverage - careplusvn.com
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%EPS Growth Rate - dars.gov.et
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%Consensus Forecast Report - dars.gov.et
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%Share Repurchase Impact - dars.gov.et
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%Slow Growth Warning - dars.gov.et
Molecular Partners (NASDAQ:MOLN) Shares Up 6.4%Still a Buy? - MarketBeat
MOLN Holds Steady at $3.93 as Molecular Partners Consolidates Within RangeTriple Bottom - careplusvn.com
Molecular Partners reports progress in MP0317 clinical trial - grafa.com
MOLN Q4 2025 Earnings: Narrowed Loss Beats Estimates as Stock Declines MarginallyRevenue Growth Outlook - dars.gov.et
MOLN Q4 2025 Earnings: Narrowed Loss Beats Estimates as Stock Declines MarginallyOperating Margin Analysis - dars.gov.et
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress By Investing.com - Investing.com Nigeria
Molecular Partners advances MP0712 cancer trial - grafa.com
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress - Investing.com
Molecular Partners and Orano Med dose first patients in MP0712 trial - scanx.trade
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
A3CSB5 Forecast — Price Target — Prediction for 2027 - TradingView
A3CSB5 Forecast — Price Target — Prediction for 2027 - TradingView
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political PressureNovartis - Benzinga
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - GlobeNewswire Inc.
MOLN - Finviz
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 - GlobeNewswire Inc.
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences - GlobeNewswire Inc.
Molecular Partners reports phase 1 data for cancer drug MP0317 By Investing.com - Investing.com Australia
Molecular Partners reports phase 1 data for cancer drug MP0317 - Investing.com
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling - GlobeNewswire Inc.
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 20.4% in April - MarketBeat
Head & ShouldersStock ScreenerCharts - Finviz
Molecular Partners (NASDAQ:MOLN) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Molecular Partners stock rating at buy - Investing.com
H.C. Wainwright reiterates Molecular Partners stock rating at buy By Investing.com - Investing.com South Africa
Molecular Partners (NASDAQ:MOLN) Stock Price Up 5%Still a Buy? - MarketBeat
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting - GlobeNewswire Inc.
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):